Market Cap 107.00M
Revenue (ttm) 0.00
Net Income (ttm) -61.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,908,100
Avg Vol 1,622,568
Day's Range N/A - N/A
Shares Out 72.30M
Stochastic %K 33%
Beta -0.32
Analysts Strong Sell
Price Target $7.29

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
Jkm11
Jkm11 May. 16 at 12:28 AM
$BMEA load up today to fill my bags.
0 · Reply
Jkm11
Jkm11 May. 16 at 12:28 AM
0 · Reply
BiomeaIR
BiomeaIR May. 15 at 7:23 PM
$BMEA leadership will be participating in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. 🗓 Tuesday, May 19th ⏰ 3:00–3:30 PM ET | 12:00–12:30 PM PT 📍 NASDAQ World Headquarters, New York, NY Register → https://bit.ly/biomea-hcwainwright-2026-stocktwits A replay will be available on the Biomea Fusion website. For 1:1 meeting requests, please reach out to [email protected].
1 · Reply
ZZTopBeard
ZZTopBeard May. 15 at 6:53 PM
$BMEA Will re enter IF & when it goes in the $1.10‘s - and then only for a quick swing over the obesity data release, before the next offering hits. Science 👍🏼 Finances 👎🏼 Management 👎🏼 Those who claim that “science always comes out top“ in the markets should not be allowed to leave the house with more than $10 in their pockets.
0 · Reply
Newcar
Newcar May. 15 at 6:44 PM
$BMEA Come on! Push it under $1 👍👍👍
0 · Reply
Newcar
Newcar May. 15 at 6:43 PM
$BMEA The stock price is skyrocketing for this company that has found a cure for diabetes. There's great market confidence.🤣🤣🤣🤣
0 · Reply
Richmonddawg
Richmonddawg May. 15 at 6:12 PM
$BMEA The lowest close ever was .9573 so I am not to worried about it going .80 again since it has never been there.
0 · Reply
ParallelPort
ParallelPort May. 15 at 4:23 PM
$BMEA We did not hit my 1.75 on the last run with a rejectin of 1.73 twice befire consolidating back around the 1.50 floor. Now that it broke 1.28 is again your strongest resistance with slight resistance at 1.20 before bottom floor around 1.09. I will do the same as the last two times, starter at 1.28 with a tight stop after it holds 1.50.
0 · Reply
CBARRR8
CBARRR8 May. 15 at 3:22 PM
$BMEA AREN'T YOU GLAD YOU DIDN"T LISTEN TO CRAZY
0 · Reply
aquira
aquira May. 15 at 2:56 PM
$BMEA foooken weak crap. We're probably headed to 0.80 to 0.90 again. Very frustrating.
1 · Reply
Latest News on BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 3 days ago

Biomea Fusion to Participate at Upcoming Investor Conferences


Biomea Fusion reports Q1 EPS (17c), consensus (19c)

2026-05-11T23:09:08.000Z - 4 days ago

Biomea Fusion reports Q1 EPS (17c), consensus (19c)


Biomea Fusion Transcript: Status update

May 5, 2026, 2:30 PM EDT - 10 days ago

Biomea Fusion Transcript: Status update


Biomea Fusion initiated with an Outperform at Citizens

2026-05-05T08:25:12.000Z - 10 days ago

Biomea Fusion initiated with an Outperform at Citizens


Biomea Fusion Transcript: Study result

Apr 28, 2026, 8:30 AM EDT - 17 days ago

Biomea Fusion Transcript: Study result


Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 3:00 PM EDT - 6 weeks ago

Biomea Fusion Transcript: Fireside chat


Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 1:00 PM EDT - 6 weeks ago

Biomea Fusion Transcript: Fireside chat


Biomea Fusion management to meet virtually with Craig-Hallum

2026-03-04T15:46:54.000Z - 2 months ago

Biomea Fusion management to meet virtually with Craig-Hallum


Biomea Fusion initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:23.000Z - 4 months ago

Biomea Fusion initiated with a Buy at Rodman & Renshaw


Biomea Fusion announces KOL presentation

2025-12-10T01:05:10.000Z - 5 months ago

Biomea Fusion announces KOL presentation


Biomea Fusion presents COVALENT-111 study results at WCIRDC

2025-12-05T12:10:07.000Z - 5 months ago

Biomea Fusion presents COVALENT-111 study results at WCIRDC


Biomea Fusion price target lowered to $6 from $7 at Citi

2025-11-10T11:35:48.000Z - 6 months ago

Biomea Fusion price target lowered to $6 from $7 at Citi


Biomea Fusion reports Q3 EPS (27c), consensus (29c)

2025-11-04T22:01:16.000Z - 6 months ago

Biomea Fusion reports Q3 EPS (27c), consensus (29c)


Biomea Fusion Transcript: Study Result

Oct 7, 2025, 8:30 AM EDT - 7 months ago

Biomea Fusion Transcript: Study Result


Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 7 months ago

Biomea Fusion Announces Proposed Public Offering of Securities


Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 11 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 1 year ago

Biomea Fusion Announces Leadership Transition


Biomea Fusion Transcript: Status Update

Mar 19, 2025, 1:00 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update


Biomea Fusion Transcript: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Transcript: Study Result


Biomea Fusion Transcript: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: Study Update


Biomea Fusion Transcript: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update


Jkm11
Jkm11 May. 16 at 12:28 AM
$BMEA load up today to fill my bags.
0 · Reply
Jkm11
Jkm11 May. 16 at 12:28 AM
0 · Reply
BiomeaIR
BiomeaIR May. 15 at 7:23 PM
$BMEA leadership will be participating in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. 🗓 Tuesday, May 19th ⏰ 3:00–3:30 PM ET | 12:00–12:30 PM PT 📍 NASDAQ World Headquarters, New York, NY Register → https://bit.ly/biomea-hcwainwright-2026-stocktwits A replay will be available on the Biomea Fusion website. For 1:1 meeting requests, please reach out to [email protected].
1 · Reply
ZZTopBeard
ZZTopBeard May. 15 at 6:53 PM
$BMEA Will re enter IF & when it goes in the $1.10‘s - and then only for a quick swing over the obesity data release, before the next offering hits. Science 👍🏼 Finances 👎🏼 Management 👎🏼 Those who claim that “science always comes out top“ in the markets should not be allowed to leave the house with more than $10 in their pockets.
0 · Reply
Newcar
Newcar May. 15 at 6:44 PM
$BMEA Come on! Push it under $1 👍👍👍
0 · Reply
Newcar
Newcar May. 15 at 6:43 PM
$BMEA The stock price is skyrocketing for this company that has found a cure for diabetes. There's great market confidence.🤣🤣🤣🤣
0 · Reply
Richmonddawg
Richmonddawg May. 15 at 6:12 PM
$BMEA The lowest close ever was .9573 so I am not to worried about it going .80 again since it has never been there.
0 · Reply
ParallelPort
ParallelPort May. 15 at 4:23 PM
$BMEA We did not hit my 1.75 on the last run with a rejectin of 1.73 twice befire consolidating back around the 1.50 floor. Now that it broke 1.28 is again your strongest resistance with slight resistance at 1.20 before bottom floor around 1.09. I will do the same as the last two times, starter at 1.28 with a tight stop after it holds 1.50.
0 · Reply
CBARRR8
CBARRR8 May. 15 at 3:22 PM
$BMEA AREN'T YOU GLAD YOU DIDN"T LISTEN TO CRAZY
0 · Reply
aquira
aquira May. 15 at 2:56 PM
$BMEA foooken weak crap. We're probably headed to 0.80 to 0.90 again. Very frustrating.
1 · Reply
aquira
aquira May. 15 at 2:39 PM
$BMEA high probability that this will continue spiraling down. It's been crashing from 2.25 last month. In a week or two, this will settle at 0.80 to 0.90 again for 6 months to 1 year without moving. Fooken frustrating. Should have sold when I was so much green at 2.20+. Now I'm barely break even. Fooookennn helllll
1 · Reply
Newcar
Newcar May. 15 at 2:25 PM
$BMEA Only a $100 million market cap for a company that claims to have a disease-modifying therapy for diabetes? Don't be fooled. They're stealing your money.
1 · Reply
10xMoonstocks
10xMoonstocks May. 15 at 2:19 PM
$BMEA It didnt hit those levels during the last big drop. What makes you think it will this time with data readouts closer than before and cash runway solidified into F27? I get you like to spread fud, but you have no factual basis for your shit
3 · Reply
Jkm11
Jkm11 May. 15 at 1:41 PM
$BMEA loaded a few.
0 · Reply
aquira
aquira May. 15 at 10:54 AM
$BMEA looks like 0.80-0.90 is near. Next news is probably 6 months away and this has lost steam in 3 weeks down 35%. Without news it will linger around 0.80-0.90 for months and will probably start moving up around December
1 · Reply
Newcar
Newcar May. 15 at 10:40 AM
$BMEA I have seen many companies that claimed to have innovative therapies go bankrupt....
1 · Reply
BioFlare
BioFlare May. 14 at 9:59 PM
$BMEA You ain’t the only one buying
1 · Reply
Creisi
Creisi May. 14 at 8:35 PM
$BMEA I was asked how likely is BMEA to announce a major partnership soon? I expect there is a 90% chance of a partnership upon release of the BMF-650 Phase 1 trial data. I say this because the oral obesity market is the highest-stakes sector in biopharma. While Phase I data is normally considered too early for partnerships, the massive demand for oral weight-loss drugs alters the conventional probability metrics drastically. This high probability is driven by the Big Pharma Feeding Frenzy. Big Pharma players lacking a GLP-1 (J&J, Sanofi, BMS, Roche) are desperate for a small-molecule tolerable GLP-1. An oral option out-performing Lilly’s orforglipron with minimal tolerability issues would trigger a big bidding war. IMO the partnership will happen within 4 wks of the data release. I base this on BMEA’s desire to focus on Icovamenib, the costs of running future phase 3 trials for a GLP-1 & Big Pharma’s relentless hunt for a well tolerated, efficacious oral GLP-1 small molecule drug.
1 · Reply
septrading
septrading May. 14 at 7:50 PM
$BMEA gonna push me right up to 200k shares at this rate.
1 · Reply
Creisi
Creisi May. 14 at 5:34 PM
$BMEA For the reasons I state below everyone holding BMEA should facilitate actions to maximize a short squeeze. The number one thing we all need to do is "Weaponize Your Block Against the Shorts". Confirming your shares are not being lent out remains the highest-priority move today. By removing your shares from the lendable float strips short sellers of the ammunition they need to manipulate the stock lower ahead of June. Most brokers and brokerages automatically set the default on their systems to allow for share lending. Go to your broker, brokerage or on line system and request your shares are not to be lent out. By doing this you remove the shares which shorts use to destroy the share value... it will also cause an even larger short squeeze. It is estimated that 90% of retail shareholders have no idea their shares are being lent to shorts! This you should do immediately!
3 · Reply
Creisi
Creisi May. 14 at 5:24 PM
$BMEA PART 1 of 2 on the current market setup as I see it. When analyzing BMEA right now there is a”Liquidity Bottleneck”; meaning the physical borrow pool is incredibly restricted at only 5,000 shares, down from 10,000 it the last couple of days. FTD history shows a brittle clearing market. If a buying catalyst occurs, such as BMF-650 positive data with more than 5% weight loss, shorts cannot easily find shares to cover, which acts as a major accelerant. This accelerant will happen quickly and remain in play for at least 3 days. That’s because there is a “High Short Floating Base”. With 24.34% of the float shorted, a massive chunk of the traded stock must eventually be bought back. On top of that we have 8.0 Days to Cover for short positions. This means a squeeze would not be a one-hour flash event; it would likely play out over multiple trading sessions which I would estimate to be at least 3 days . (Continued to Part 2 posted below)
1 · Reply
Creisi
Creisi May. 14 at 5:17 PM
$BMEA Good point. The main scientific reason why Kura's Menin inhibitor is very different, is because it is a non-covalent drug. In layman's terms, their Menin inhibitor drug requires continued dosing to achieve desired effects and once stopped, the drug effect stops. This is opposite of Icovamenib which is covalent; so it permanently binds to the target for 24/7 continuous activity even after the drug is stopped. This incredible characteristic is unique to Icovamenib and BMF-650 and gives them a massive long term drug efficacy advantage.
1 · Reply